Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab and Peanut Oral Immunotherapy for Peanut Allergy
NCT00932282Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jul 2009
- Primary completion
- Aug 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in peanut allergy, sponsored by University of North Carolina at Chapel Hill. Started Jul 2009; status: completed.
02
Drugs
omalizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT00932282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00932282.